US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 19:18:24 Source:politicsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
You may also like
- Celebrity birthdays for the week of May 26
- Chris Pratt divides fans as he publicly snubs ex
- Khloe Kardashian takes True and Tatum to see dad Tristan Thompson play for the FIRST TIME
- Katharina Wagner will lead the Bayreuth Festival for 5 more years
- Pentagon vows to keep weapons moving to Ukraine as Kyiv faces a renewed assault by Russia
- I am a Cher superfan
- Chris Pratt divides fans as he publicly snubs ex
- Antiques Roadshow guest is left stunned at his 'over the top' belt buckle's shocking real price
- Mystery artist who erected signs comparing pothole